are effectively removed from manufacturing equipment to prevent cross-contamination. This is integral to maintaining pharma QA standards and complying with regulatory expectations outlined in guidelines such as FDA 21 CFR Part 211, EU GMP Volume 4 Annex 15, and PIC/S GMP.

One key regulatory expectation is that cleaning limits be based on a scientific rationale rather than arbitrary values. Toxicology and PDE provide this foundation by quantifying the acceptable residual levels of compounds considering their inherent toxicity and exposure risks. The PDE is a toxicologically derived threshold representing the maximum acceptable intake of a chemical daily without significant health risk.

Before starting, it is important to understand the following key concepts:

• Toxicology: The study of adverse effects of chemical substances on living organisms, essential in evaluating safety limits.
• Permitted Daily Exposure (PDE): A calculated value that indicates the maximum safe amount of residual substance allowed per day based on toxicological data and safety factors.
• Cleaning Limits: The acceptable amount of residue permitted on manufacturing surfaces post-cleaning, expressed in units such as micrograms per cm² or parts per million (ppm).
• Validation Lifecycle: The entire process from process design, qualification through process validation, and ongoing CPV to ensure consistent product quality.

In this guide, we will provide a practical approach to integrating toxicology and PDE calculations into your cleaning validation strategy, emphasizing compliance with FDA, EMA, and MHRA regulations.

Step 1: Gathering Toxicological Data Relevant to Your Product

The first step in calculating cleaning limits using toxicology and PDE references is to acquire accurate, comprehensive toxicological data on the substances involved. This includes the API(s), cleaning agents, and any potential contaminants. Sources for reliable toxicological data include pharmacopoeia monographs, safety data sheets, scientific literature, and regulatory submissions.

Substep 1.1: Identify the Substance(s) of Concern

Determine which compounds require cleaning limit calculation. These normally include:

• The previous product or intermediate residues
• Cleaning agents or solvents used
• Degradation products or impurities with significant toxicity

Substep 1.2: Obtain Toxicological Endpoints

Collect critical toxicological endpoints, essential for PDE derivation, such as:

• NOAEL (No Observed Adverse Effect Level)
• LOAEL (Lowest Observed Adverse Effect Level)
• Carcinogenicity data
• Genotoxicity and mutagenicity data
• Reproductive and developmental toxicity

This data is often generated via preclinical and clinical studies assessed during drug registration and should be extracted carefully to avoid misinterpretation.

Substep 1.3: Assess Available PDE Values

Many products and substances may already have published PDEs in the ICH Q3C (Impurities: Residual Solvents), ICH Q3D (Elemental Impurities), or EMA guidance documents. If these are not available, individual toxicology data must be evaluated to derive a PDE using well-established methodologies.

Understanding the PDE methodology is critical for a clean and defensible cleaning validation package. The PDE calculation incorporates conservative safety factors applied to toxicological endpoints to cover uncertainties and interspecies differences. This is a core principle embedded in regulatory guidance across the US, UK, and EU jurisdictions.

Step 2: Calculating the Permitted Daily Exposure (PDE)

With toxicological data in hand, the next step is to calculate or confirm the PDE value. PDE represents the threshold amount of residual substance a patient can be exposed to daily without adverse effects.

Substep 2.1: PDE Calculation Formula

The classical PDE equation recommended by ICH Q3A and ICH Q3D can be summarized as follows:

PDE = (NOAEL or LOAEL) × Body Weight / (F1 × F2 × F3 × F4 × F5)

• NOAEL or LOAEL: The point of departure from toxicology studies (mg/kg/day).
• Body Weight: Usually 50 kg for conservative adult estimation.
• F1: Factor for extrapolation between species (e.g., rat to human).
• F2: Factor for variability within the human population.
• F3: Factor for duration of exposure (e.g., subchronic to chronic extrapolation).
• F4: Factor for severity of toxicity if applicable.
• F5: Factor for quality of the data or other specific considerations.

This formula incorporates toxicological uncertainty to produce a biologically safe exposure limit.

Substep 2.2: Special Considerations in PDE Derivation

During PDE calculation, careful scrutiny should be given to:

• Additional safety factors for genotoxic or carcinogenic compounds, possibly requiring a non-threshold approach.
• Considering vulnerable populations if applicable (e.g., pediatric patients).
• The duration of patient treatment and cumulative exposure.

Substep 2.3: Validation and Review of PDE Values

Once calculated, PDE values should be reviewed by toxicology experts, clinical teams, and QA. Cross-referencing with guidance from EMA Q3D guidelines and the FDA’s pharmaceutical quality resources ensures regulatory alignment.

Step 3: Determining Cleaning Limits Using the PDE

With PDE values established, the next essential stage is translating these into practical cleaning limits for manufacturing equipment to comply with cleaning validation requirements.

Substep 3.1: Calculating Cleaning Limits Based on PDE

Cleaning limits are typically calculated to ensure that residues remaining after cleaning do not lead to patient exposure above the PDE. The following formula is generally applied:

Cleaning Limit (mg) = PDE × Maximum Daily Dose of Next Product / Body Weight

However, since different products might have varying daily doses, the next product’s maximum clinical dose is critical for risk assessment to the subsequent batch.

Substep 3.2: Considerations for Surface Area and Swab Recovery

Cleaning limits can be expressed in terms of mass (mg) or concentration (ppm), but for practical environmental monitoring, it is essential to convert limits to residues per unit surface area:

Cleaning Limit (µg/cm²) = Cleaning Limit (mg) × 1000 / Surface Area (cm²) / Recovery Factor

• Surface Area: The total contact surface area of the equipment to be cleaned.
• Recovery Factor: Account for inefficiencies and variability in swab or rinse sampling recovery, typically between 0.5 and 1.0.

This ensures that sampling limits used during routine cleaning validation are realistic and achievable.

Substep 3.3: Other Approaches and Limits

In some cases, alternative limit-setting methods are used, such as:

• 10 ppm limit based on total carryover (as a backstop approach)
• 1/1000th of therapeutic dose (an older, conservative heuristic)
• Health-based exposure limits derived from toxicological evaluation

However, health-based exposure limits anchored in PDE calculations are preferred and increasingly mandated by regulatory authorities.

Step 4: Integrating Cleaning Limits into the Validation Lifecycle

Establishing cleaning limits through toxicology and PDE calculations is part of the broader validation lifecycle, encompassing process validation, Product and Process Qualification (PPQ), and continued process verification (CPV). The following outlines integration steps for pharma manufacturing stakeholders.

Substep 4.1: Incorporate Limits into Cleaning Validation Protocols

Cleaning limits should be clearly stated in the cleaning validation master plan and protocols. These limits guide sampling strategy, analytical method sensitivity, and pass/fail criteria. Validation protocols must outline:

• Sampling locations and methods
• Analytical detection methods and validation status
• Acceptance criteria based on the cleaning limits calculated

Early alignment with quality assurance and regulatory affairs teams ensures harmonized expectations across US, UK, and EU jurisdictions.

Substep 4.2: Conduct Cleaning Validation Studies

Following approved protocols, studies are performed demonstrating that the cleaning process consistently achieves residue levels below the calculated limits. This is imperative for GMP compliance and product safety.

Cleaning validation results must document method robustness, swab recovery efficiency, and reproducibility of cleaning procedures. Confirmation of analytical method specificity and limit of quantification (LOQ) below the cleaning limit strengthens control assurance.

Substep 4.3: Link Cleaning Limits to Ongoing CPV

Cleaning validation is not a one-time activity but part of ongoing product lifecycle management through CPV. Regular cleaning performance monitoring—via environmental sampling, swipe tests, and periodic cleaning revalidation—should reference the predefined cleaning limits.

CPV activities help detect changes in process performance, equipment condition, or cleaning agent efficacy. Deviations from accepted cleaning limits trigger investigations and corrective actions, maintaining robust process control standards.

Substep 4.4: Documentation and Regulatory Expectations

All activities around cleaning limit derivation, validation studies, and CPV data must be documented meticulously. This serves as evidence of compliance to inspectors and auditors from FDA, MHRA, EMA, and global agencies aligned with PIC/S standards.

Regulatory inspectors expect a thorough risk-based, science-driven approach grounded in toxicology and PDE values, demonstrating continuous control and patient safety focus throughout the cleaning validation lifecycle.

Step 5: Common Challenges and Best Practices

In implementing toxicology and PDE-based cleaning limits, several challenges and best practices should be considered to ensure success and regulatory alignment:

Challenge 5.1: Data Availability and Interpretation

Access to complete and quality toxicological data can be limited, especially for legacy APIs or excipients. Collaborating with toxicologists and utilizing recognized databases and regulatory dossiers can overcome this hurdle.

Best Practice 5.1:

• Engage cross-functional teams early in validation planning.
• Use validated models and conservative assumptions when data gaps exist.

Challenge 5.2: Analytical Method Sensitivity

Analytical methods must reliably detect residues below the established cleaning limits, demanding robust validation and sensitivity.

Best Practice 5.2:

• Develop and validate specific methods capable of meeting or exceeding cleaning limit LOQs.
• Use orthogonal methods where appropriate to increase confidence.

Challenge 5.3: Managing Multiple Products and Cross-Contamination Risk

In multi-product facilities, cleaning limits must be tailored for each transition product pair using appropriate PDE values to manage cross-contamination risks effectively.

Best Practice 5.3:

• Maintain a comprehensive residue limit matrix for all product sequences.
• Apply conservative limits where toxicological data is uncertain.

Challenge 5.4: Regulatory Changes and Continuous Improvement

Keeping pace with evolving regulations in the US, UK, and EU necessitates routine review of toxicological guidance and PDE methodologies.

Best Practice 5.4:

• Implement a document review and update process within the quality system.
• Train staff on changes in guidelines such as ICH updates and MHRA guidances.

By adhering to these best practices, pharmaceutical manufacturers can ensure a robust cleaning validation program that centers on patient safety and regulatory compliance.

Conclusion and Regulatory Considerations

The integration of toxicology and PDE evaluations within cleaning limit calculations forms the cornerstone of scientifically justified cleaning validation strategies. This approach aligns with expectations from regulators across the US, UK, and EU, including MHRA GMP Annex 15 on Validation Lifecycle and the FDA’s guidance on cleaning processes.

Implementing these steps—gathering toxicology data, calculating PDEs, deriving cleaning limits, and embedding them into the validation lifecycle with ongoing CPV—ensures a GMP-compliant, risk-based approach to controlling cross-contamination. This ultimately protects patient safety and supports reliable pharmaceutical manufacturing operations.

Pharmaceutical professionals across clinical operations, regulatory affairs, medical affairs, and manufacturing should incorporate this methodology into their cleaning validation and process validation efforts for improved control and audit readiness.